Narcolepsy type 1 (NT1) is a lifelong sleep disorder, primarily characterized clinically by excessive daytime sleepiness and cataplexy and pathologically by the loss of hypocretinergic neurons in the lateral hypothalamus. Despite being a rare disorder, the NT1-related burden for patients and society is relevant due to the early onset and chronic nature of this condition. Although the etiology of narcolepsy is still unknown, mounting evidence supports a central role of autoimmunity. To date, no cure is available for this disorder and current treatment is symptomatic. Based on the hypothesis of the autoimmune etiology of this disease, immunotherapy could possibly represent a valid therapeutic option. However, contrasting and limited results have been provided so far. This review discusses the evidence supporting the use of immunotherapy in narcolepsy, the outcomes obtained so far, current issues and future directions.

Reviewing the clinical implications of treating narcolepsy as an autoimmune disorder / Giannoccaro, M. P.; Liguori, R.; Plazzi, G.; Pizza, F.. - In: NATURE AND SCIENCE OF SLEEP. - ISSN 1179-1608. - 13:(2021), pp. 557-577. [10.2147/NSS.S275931]

Reviewing the clinical implications of treating narcolepsy as an autoimmune disorder

Plazzi G.;
2021

Abstract

Narcolepsy type 1 (NT1) is a lifelong sleep disorder, primarily characterized clinically by excessive daytime sleepiness and cataplexy and pathologically by the loss of hypocretinergic neurons in the lateral hypothalamus. Despite being a rare disorder, the NT1-related burden for patients and society is relevant due to the early onset and chronic nature of this condition. Although the etiology of narcolepsy is still unknown, mounting evidence supports a central role of autoimmunity. To date, no cure is available for this disorder and current treatment is symptomatic. Based on the hypothesis of the autoimmune etiology of this disease, immunotherapy could possibly represent a valid therapeutic option. However, contrasting and limited results have been provided so far. This review discusses the evidence supporting the use of immunotherapy in narcolepsy, the outcomes obtained so far, current issues and future directions.
2021
13
557
577
Reviewing the clinical implications of treating narcolepsy as an autoimmune disorder / Giannoccaro, M. P.; Liguori, R.; Plazzi, G.; Pizza, F.. - In: NATURE AND SCIENCE OF SLEEP. - ISSN 1179-1608. - 13:(2021), pp. 557-577. [10.2147/NSS.S275931]
Giannoccaro, M. P.; Liguori, R.; Plazzi, G.; Pizza, F.
File in questo prodotto:
File Dimensione Formato  
NSS-275931-reviewing-the-clinical-implications-of-treating-narcolepsy-a.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 2.4 MB
Formato Adobe PDF
2.4 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1251592
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 8
social impact